Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
27.83%
Operating Margin
9.82%
Net Margin
7.51%
Efficiency Metrics
Revenue per Expense Ratio
1.13
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
12.32%
Income Tax Rate
7.90%
EPS
6.6200000000
Balance Sheet Analysis
Current Ratio
2.46
Cash Ratio
0.46
Working Capital
$1.06B
Debt to Equity
0.52
Debt to Assets
26.38%
Equity Ratio
50.60%
Cash Flow Analysis
Operating Cash Flow Ratio
12.76%
Free Cash Flow Ratio
10.35%
CapEx to Revenue
2.41%
Dividends Paid
$34.48M
Stock Buybacks
$95.69M
Total Shareholder Returns
$130.17M
Cash Position Change
-3.85%
Key Takeaways (2024 FY)
Revenue declined by 3.4166186024351%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 21.24%
Detailed Growth Metrics
Core Performance
Revenue
-3.42%
Net Income
53.06%
EPS
53.60%
Operating Income
18.92%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
8.11%
Operating Cash Flow
63.26%
Free Cash Flow
93.86%
Balance Sheet Health
Assets
-4.17%
Debt
-21.24%
Book Value per Share
9.93%
Inventory
-12.55%
Shareholder Returns
Dividends per Share
21.24%
Shares Outstanding
-0.34%
Long Term Trends
3Y Revenue/Share
25.84%
5Y Revenue/Share
32.78%
3Y Dividend/Share
21.00%
5Y Dividend/Share
20.67%